A real-world safety surveillance study of aducanumab through the FDA adverse event reporting system

A real-world safety surveillance study of aducanumab through the FDA adverse event reporting system

BackgroundAlzheimer’s disease poses a major public health challenge, with aducanumab’s approval in 2021 as the first disease-modifying therapy raising important safety considerations. This study analyzed the Food Drug Administration Adverse Event Reporting System (FAERS) database to evaluate aducanu...

Full description

Bibliographic Details
Main Authors: Jingjing Huang, Xiaohong Long, Chunyong Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-03-01
Series:Frontiers in Pharmacology
Subjects:
food drug administration adverse event reporting system (FAERS)
aducanumab
monoclonal antibody selectively target
real-world study
adverse events
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1522058/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2025.1522058/full

Similar Items